Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001193125-25-092139
Filing Date
2025-04-24
Accepted
2025-04-24 06:08:54
Documents
7

Document Format Files

Seq Description Document Type Size
1 DEFA14A d940377ddefa14a.htm DEFA14A 28753
2 GRAPHIC g940377dsp03.jpg GRAPHIC 3500
3 GRAPHIC g940377dsp03a.jpg GRAPHIC 27631
4 GRAPHIC g940377dsp03b.jpg GRAPHIC 18447
5 GRAPHIC g940377dsp03c.jpg GRAPHIC 2182
6 GRAPHIC g940377dsp03d.jpg GRAPHIC 2749
7 GRAPHIC g940377dsp4b.jpg GRAPHIC 828
  Complete submission text file 0001193125-25-092139.txt   106831
Mailing Address 1325 BOYLSTON STREET SUITE 401 BOSTON MA 02215
Business Address 1325 BOYLSTON STREET SUITE 401 BOSTON MA 02215 857-321-8020
Rapport Therapeutics, Inc. (Filer) CIK: 0002012593 (see all company filings)

EIN.: 880724208 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-42121 | Film No.: 25863446
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)